Literature DB >> 15135197

Optimal dosing of dobutamine for treating post-resuscitation left ventricular dysfunction.

Alejandro Vasquez1, Karl B Kern, Ronald W Hilwig, Joseph Heidenreich, Robert A Berg, Gordon A Ewy.   

Abstract

OBJECTIVES: This study was designed to determine the optimal dose of dobutamine in the treatment of post-resuscitation left ventricular dysfunction.
BACKGROUND: Global left ventricular dysfunction following successful resuscitation from prolonged, ventricular fibrillation cardiac arrest, negatively impacts long-term survival. Dobutamine can overcome this global myocardial stunning. Previous data indicate a dose of 10 mcg/kgmin improves systolic and diastolic function, but markedly increases the heart rate.
METHODS: Twenty swine (24 +/- 0.4 kg) were randomized to one of four doses (0, 2, 5, and 7.5 mcg/kgmin) of dobutamine for the treatment of post-resuscitation myocardial dysfunction following 12.5 min of untreated ventricular fibrillation cardiac arrest. Cardiac function was measured at pre-arrest baseline and serially for 6 h post-resuscitation. Left ventricular function was evaluated by contrast ventriculograms, left ventricular pressures, +dP/dt, Tau, -dP/dt, and cardiac output. Myocardial oxygen consumption and myocardial blood flow were measured to assess the functional significance of any dobutamine-mediated heart rate responses.
RESULTS: Left ventricular dysfunction was evident at 25 min and peaked 4 h post-resuscitation. Significant (P < 0.05) improvements in ventricular systolic (EF, CO) and diastolic (LVEDP, Tau) function were evident within minutes of dobutamine initiation and persisted at 6h for the 5 and 7.5 mcg/kgmin groups. Tachycardia manifested with all dobutamine doses, but only affected myocardial oxygen consumption significantly (P < 0.05) at the highest dose (7.5 mcg/kgmin).
CONCLUSIONS: Dobutamine at 5 mcg/kgmin appears optimal for restoring systolic and diastolic function post-resuscitation without adversely affecting myocardial oxygen consumption.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135197     DOI: 10.1016/j.resuscitation.2004.01.002

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  19 in total

1.  Part 10: Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

Authors:  Monica E Kleinman; Allan R de Caen; Leon Chameides; Dianne L Atkins; Robert A Berg; Marc D Berg; Farhan Bhanji; Dominique Biarent; Robert Bingham; Ashraf H Coovadia; Mary Fran Hazinski; Robert W Hickey; Vinay M Nadkarni; Amelia G Reis; Antonio Rodriguez-Nunez; James Tibballs; Arno L Zaritsky; David Zideman
Journal:  Circulation       Date:  2010-10-19       Impact factor: 29.690

2.  Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.

Authors:  Monica E Kleinman; Allan R de Caen; Leon Chameides; Dianne L Atkins; Robert A Berg; Marc D Berg; Farhan Bhanji; Dominique Biarent; Robert Bingham; Ashraf H Coovadia; Mary Fran Hazinski; Robert W Hickey; Vinay M Nadkarni; Amelia G Reis; Antonio Rodriguez-Nunez; James Tibballs; Arno L Zaritsky; David Zideman
Journal:  Pediatrics       Date:  2010-10-18       Impact factor: 7.124

Review 3.  Pediatric cardiopulmonary resuscitation: advances in science, techniques, and outcomes.

Authors:  Alexis A Topjian; Robert A Berg; Vinay M Nadkarni
Journal:  Pediatrics       Date:  2008-11       Impact factor: 7.124

4.  Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model.

Authors:  James T Niemann; Scott Youngquist; John P Rosborough; Atman P Shah; Quynh T Phan; Scott G Filler
Journal:  Crit Care Med       Date:  2010-04       Impact factor: 7.598

5.  Effects of mild hypothermia on hemodynamics in cardiac arrest survivors and isolated failing human myocardium.

Authors:  Claudius Jacobshagen; Theresa Pelster; Anja Pax; Wiebke Horn; Stephan Schmidt-Schweda; Bernhard W Unsöld; Tim Seidler; Stephan Wagner; Gerd Hasenfuss; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-04       Impact factor: 5.460

Review 6.  Protecting mitochondrial bioenergetic function during resuscitation from cardiac arrest.

Authors:  Raúl J Gazmuri; Jeejabai Radhakrishnan
Journal:  Crit Care Clin       Date:  2012-04       Impact factor: 3.598

7.  Ivabradine in acute heart failure: Effects on heart rate and hemodynamic parameters in a randomized and controlled swine trial.

Authors:  Marina Pascual Izco; Rafael Ramírez-Carracedo; Ignacio Hernández Navarro; Álvaro Osorio Ruiz; Borja Castejón Navarro; Irene Cuadrado Berrocal; Carlota Largo Aramburu; Gonzalo Luis Alonso Salinas; Javier Díez; Marta Saura Redondo; José Luis Zamorano; Carlos Zaragoza; Marcelo Sanmartín
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

8.  Postresuscitation myocardial dysfunction: correlated factors and prognostic implications.

Authors:  Wei-Tien Chang; Matthew Huei-Ming Ma; Kuo-Liong Chien; Chien-Hua Huang; Min-Shan Tsai; Fuh-Yuan Shih; Ann Yuan; Kuang-Chau Tsai; Fang-Yue Lin; Yuan-Teh Lee; Wen-Jone Chen
Journal:  Intensive Care Med       Date:  2006-11-15       Impact factor: 17.440

9.  Burst stimulation improves hemodynamics during resuscitation after prolonged ventricular fibrillation.

Authors:  Gregory Walcott; Sharon Melnick; Cheryl Killingsworth; Raymond Ideker
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-02

10.  European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care.

Authors:  Jerry P Nolan; Claudio Sandroni; Bernd W Böttiger; Alain Cariou; Tobias Cronberg; Hans Friberg; Cornelia Genbrugge; Kirstie Haywood; Gisela Lilja; Véronique R M Moulaert; Nikolaos Nikolaou; Theresa Mariero Olasveengen; Markus B Skrifvars; Fabio Taccone; Jasmeet Soar
Journal:  Intensive Care Med       Date:  2021-03-25       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.